Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 28 Dec 22 424B5 Prospectus supplement for primary offering
- 15 Nov 21 424B5 Prospectus supplement for primary offering
- 21 Jan 21 424B5 Prospectus supplement for primary offering
- 19 Jan 21 424B5 Prospectus supplement for primary offering
- 10 Dec 20 424B5 Prospectus supplement for primary offering
- 23 Jul 20 424B5 Prospectus supplement for primary offering
- 9 Jul 20 EFFECT Notice of effectiveness
-
12 Jun 20 S-3 Shelf registration
TLPH similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference, in the Prospectus constituting a part of this Registration Statement on Form S-3, of our reports dated March 16, 2020 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of AcelRx Pharmaceuticals, Inc. appearing in AcelRx Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2019.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ OUM & CO. LLP
San Francisco, California
June 12, 2020